Clinical trials: Adult Atopic Dermatitis
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- NCT05906628
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Incyte Corporation
Dermatitis, Atopic
Efalizumab for Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine if Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT00226057
- Testing
- Raptiva
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion in Adults of Atopic Dermatitis.
This study will evaluate the safety and efficacy of a moisturizer body lotion: the study aims to determine the tolerance of this product by the study population, and its effects on atopic dermatitis condition, skin hydration…
- Trial name
- NCT05062213
- Testing
- Moisturizer Body Lotion
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis (AD)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and…
- Trial name
- NCT06931990
- Testing
- LT-002-158 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Dermatitis
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are…
- Trial name
- NCT05117060
- Testing
- LEO 152020 tablet
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 216 people
- Sponsor
- JW Pharmaceutical
Moderate to Severe Atopic Dermatitis
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
- Trial name
- NCT05997927
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Healthy Participants, Atopic Dermatitis
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06564389
- Testing
- PF-07832837
- Where
- 8 sites in United States, Poland
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Pfizer
Health Adult Subjects, Atopic Dermatitis (AD)
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07782476
- Testing
- HXN6005
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Atopic Dermatitis, Atopic Dermatitis Eczema
Topical ENS-002 for Atopic Dermatitis in Adults
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.
- Trial name
- EnSync (NCT06469385)
- Testing
- ENS-002
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Concerto Biosciences
Atopic Dermatitis
Bleach Bath Treatment of Adults With Atopic Dermatitis
This is pilot, mechanistic study to address whether bleach baths given to adult subjects with atopic dermatitis or eczema, who are colonized with the bacteria Staphylococcus aureus, will significantly alter their skin microbiome…
- Trial name
- NCT01996150
- Testing
- bleach bath (sodium hypochlorite)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Rochester
Dermatitis, Atopic, Eczema
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT04800315
- Testing
- CC-93538
- Where
- 157 sites in United States, Canada and 4 more
- Volunteers
- 221 people
- Sponsor
- Celgene
Atopic Dermatitis
A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and a Lip Moisturizer in Adults of Atopic Dermatitis.
This study will test the safety and efficacy of 2 moisturizers: a body lotion and a lip moisturizer. For the moisturizer body lotion, the study aims to determine the tolerance of this product by the study population, and its…
- Trial name
- NCT04950374
- Testing
- Moisturizer Body Lotion, Lip Moisturizer
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous…
- Trial name
- NCT02210780
- Testing
- Dupilumab
- Where
- 42 sites in United States
- Volunteers
- 194 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03912259
- Testing
- Dupilumab, Emollient (moisturizer)
- Where
- 27 sites in China
- Volunteers
- 165 people
- Sponsor
- Sanofi
Pruritus, Atopic Dermatitis
Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis
The purpose of this study is to assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01605708
- Testing
- REGN846
- Where
- 14 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how…
- Trial name
- ADhope 2 (NCT06526182)
- Testing
- Lebrikizumab
- Where
- 4 sites in Spain
- Volunteers
- 520 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen…
- Trial name
- NCT00914186
- Testing
- TS022, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Pruritus, Atopic Dermatitis
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to…
- Trial name
- KARE (NCT04018027)
- Testing
- difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg
- Where
- 40 sites in United States, Canada
- Volunteers
- 401 people
- Sponsor
- Cara Therapeutics, Inc.